27.7 C
Vientiane
Friday, May 16, 2025
spot_img
Home Blog Page 911

Mitrade, Australia’s Award-Winning CFD Trading Platform, Elevates Trader Protection in an Expanding Crypto & Forex Market

MELBOURNE, Australia, Jan. 14, 2025 /PRNewswire/ — As Australia’s retail trading market matures, the focus is shifting beyond regulatory compliance to a broader culture of trader protection and financial security. Mitrade, a global award-winning Contract for Difference (CFD) trading platform, has introduced a million-dollar Excess of Loss Insurance Policy backed by Lloyd’s of London to strengthen its trader confidence.

With forex and cryptocurrency trading gaining traction in Australia, driven by greater accessibility to technology and growing financial literacy, responsible trading practices have never been more critical. While CFDs offer Australians exposure to global markets with low capital, long-term market sustainability requires more than accessibility—it demands proactive risk management.

The CFD broker operates under the Australian Securities and Investments Commission (ASIC), one of the most rigorous regulatory bodies ensuring consumer protection and market transparency. In addition to mandatory safeguards like segregated funds and professional indemnity insurance, Mitrade has secured an Excess of Loss Insurance Policy at no cost to their customers, providing coverage of up to AUD 1,000,000 for qualifying claims in the rare event of company insolvency.

Australia’s CFD trading market is built on a strong regulatory framework, continually evolving under ASIC’s oversight,” said Elven Jong, CEO of Mitrade Australia. “While these standards offer substantial trader protections, our Excess of Loss Insurance provides an additional safeguard beyond compliance. We understand traders seek enhanced fund security and comprehensive education and resources to navigate market complexities. Our commitment reflects the broader industry shift towards proactive trader support, resilience, and risk mitigation.”

The CFD broker’s dedication to trader protection and market transparency has earned industry recognition, including Best Client Fund Security Global 2024 and Best Forex Customer Satisfaction & Happiness Australia 2024 awards.

About Mitrade 

Mitrade is an award-winning CFD trading platform that originated in Melbourne, Australia. Over the years, Mitrade has gained global recognition, offering services through entities regulated by authorities – Australia’s ASIC, Cayman Islands’ CIMA, Mauritius’s FSC, and Cyprus’s CySEC. Committed to democratizing global market access, Mitrade connects users to over 700 OTC derivative financial instruments, including indices, forex, commodities, ETFs, and shares. Powered by proprietary AI-driven technology, Mitrade offers fast execution, low spreads, and robust risk management tools. Its multi-device compatibility gives users a seamless trading experience at every stage of their journey.

For more information on Mitrade, visit https://www.mitrade.com/.

Petnow Expands Its Presence in Japan with TV Recognition and Interpets 2025 Participation

Petnow to Exhibit at Interpets 2025 Held in April at Tokyo Big Sight

TOKYO, Jan. 14, 2025 /PRNewswire/ — Petnow Inc., a pioneering pet tech company, is expanding its footprint in Japan following the app’s release in October 2024. Strengthening its presence, Petnow recently received national recognition on Nippon Television’s popular show “The Doctor is Jealous Today Too” and is now gearing up to showcase its advanced technology at Interpets 2025, one of the largest and most influential pet industry events in the country.

Petnow to Exhibit at Interpets 2025 Held in April at Tokyo Big Sight
Petnow to Exhibit at Interpets 2025 Held in April at Tokyo Big Sight

The Petnow app leverages cutting-edge AI technology to offer a non-invasive biometric identification system for pets, using nose prints for dogs and facial recognition for cats. With its easy-to-use interface and unique solution for pet registration and lost pet recovery, Petnow has already caught the attention of many pet owners across Japan.

Interpets, held annually in Tokyo, is Japan’s premier international pet fair, gathering industry leaders, businesses, and pet enthusiasts from around the world. Petnow will participate in Interpets 2025 through the Korean pavilion, presenting its AI-driven lost pet recovery system, which promotes community-based search efforts by enabling real-time alerts and collaborative reunions of missing pets.

By combining innovative biometric technology with a strong community approach, Petnow is committed to improving pet safety in Japan. Through its participation in Interpets 2025 and growing local partnerships, Petnow is eager to support pet owners in building a safer and more connected environment for their beloved animals.

Name: Mr. Jinuk Jung
Email: contact@petnow.io
Phone No.: +82-10-6439-1139
Website: https://www.petnow.io/ja

O-RAN ALLIANCE Announces Its New Board of Directors for the Term 2024-2026

O-RAN ALLIANCE Logo
  • O-RAN ALLIANCE Extended Board of Directors has been elected for the upcoming 2-year term
  • Abdurazak Mudesir, Group CTO of Deutsche Telekom, was re-elected as Chair of the Board

BONN, Germany, Jan. 14, 2025 /PRNewswire/ — On December 17, 2024, the O-RAN ALLIANCE General Members Meeting concluded election of its Extended Board of Directors for the upcoming 2-year term.

O-RAN ALLIANCE welcomes China Telecom, SoftBank and UScellular as new Board members.

Current members of the Board are:

Company

Director

Alternate Director

AT&T

Yigal Elbaz

Brian Daly

Boost Mobile

Eben Albertyn

Jingyi Zhou

China Mobile

Yuhong Huang

Chih-Lin I

China Telecom

Yue Wang

Qingtian Wang

Deutsche Telekom

Abdurazak Mudesir

Petr Ledl

KDDI

Takuya Sawada

Masaaki Koga

NTT DOCOMO

Takaaki Sato

Masafumi Masuda

Orange

Claire Chauvin

Atoosa Hatefi

Rakuten Mobile

Sharad Sriwastawa

Awn Muhammad

SoftBank

Ryuji Wakikawa

Alex Jinsung Choi

Telefonica

Enrique Blanco

Jose Luis Espla

TIM

Andrea Calvi

Marco Caretti

UScellular

Michael Irizarry

Narothum Saxena

Verizon

Steven Rice

Edward Diaz

Vodafone

Nadia Benabdallah

Francisco Martin

Abdurazak Mudesir, Group CTO of Deutsche Telekom, was re-elected as Chair of the Board.

“With O-RAN ALLIANCE specifications and architecture, operators have the option to deploy Radio Access Networks that are open and secure, and enhanced with intelligent functions to optimize deployments and operations,” said Abdurazak Mudesir, Chair of the Board of O-RAN ALLIANCE and Group CTO of Deutsche Telekom. “Guided by operator priorities, O-RAN ALLIANCE remains committed to driving the transformation of the RAN toward openness, intelligence, virtualization, and full interoperability, to enable large-scale deployments in mobile networks.”

About O-RAN ALLIANCE
The O-RAN ALLIANCE is a world-wide community of mobile operators, vendors, and research & academic institutions operating in the Radio Access Network (RAN) industry. As the RAN is an essential part of any mobile network, the O-RAN ALLIANCE’s mission is to re-shape the industry towards more intelligent, open, virtualized and fully interoperable mobile networks. The new O-RAN specifications enable a more competitive and vibrant RAN supplier ecosystem with faster innovation to improve user experience. O-RAN based mobile networks at the same time improve the efficiency of RAN deployments as well as operations by mobile operators. To achieve this, the O-RAN ALLIANCE publishes new RAN specifications, releases open software for the RAN, and supports its members in integration and testing of their implementations.

For more information, please visit www.o-ran.org.

Telix Presentation to the 43rd Annual J.P. Morgan Healthcare Conference

logo

MELBOURNE, Australia and INDIANAPOLIS, Jan. 14, 2025 /PRNewswire/ — Telix Pharmaceuticals Limited (ASX: TLX, Nasdaq: TLX, Telix, the Company) today advises that Dr. Christian Behrenbruch, Managing Director and Group CEO, will be presenting this week at the 43rd Annual J.P. Morgan Healthcare Conference being held in San Francisco, CA (U.S.A.).

The presentation will take place this Wednesday, 15 January at 2:15 pm PST (5:15 pm EST / 9:15 am AEDT, 16 January).

Participants can register for the webcast at the following link and the webcast presentation can be downloaded here.

The webcast will be accessible on demand on the Telix website following the event.

About Telix Pharmaceuticals Limited

Telix is a biopharmaceutical company focused on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals and associated medical technologies. Telix is headquartered in Melbourne, Australia, with international operations in the United States, Canada, Europe (Belgium and Switzerland), and Japan. Telix is developing a portfolio of clinical and commercial stage products that aims to address significant unmet medical needs in oncology and rare diseases. Telix is listed on the Australian Securities Exchange (ASX: TLX) and the Nasdaq Global Select Market (Nasdaq: TLX).

Visit www.telixpharma.com for further information about Telix, including details of the latest share price, ASX and SEC filings, investor and analyst presentations, news releases, event details and other publications that may be of interest. You can also follow Telix on X and LinkedIn.

Telix Investor Relations

Australia
Ms. Kyahn Williamson
Telix Pharmaceuticals Limited
SVP Investor Relations and Corporate Communications
Email: kyahn.williamson@telixpharma.com

United States
Lisa Wilson
In-Site Communications
Email: lwilson@insitecony.com

Legal Notices

You should read this announcement together with our risk factors, as disclosed in our most recently filed reports with the Australian Securities Exchange (ASX), U.S. Securities and Exchange Commission (SEC), including our registration statement on Form 20-F filed with the SEC, or on our website.

The information contained in this announcement is not intended to be an offer for subscription, invitation or recommendation with respect to securities of Telix Pharmaceuticals Limited (Telix) in any jurisdiction, including the United States. The information and opinions contained in this announcement are subject to change without notification.  To the maximum extent permitted by law, Telix disclaims any obligation or undertaking to update or revise any information or opinions contained in this announcement, including any forward-looking statements (as referred to below), whether as a result of new information, future developments, a change in expectations or assumptions, or otherwise. No representation or warranty, express or implied, is made in relation to the accuracy or completeness of the information contained or opinions expressed in the course of this announcement.

This announcement may contain forward-looking statements, including within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, that relate to anticipated future events, financial performance, plans, strategies or business developments. Forward-looking statements can generally be identified by the use of words such as “may”, “expect”, “intend”, “plan”, “estimate”, “anticipate”, “believe”, “outlook”, “forecast” and “guidance”, or the negative of these words or other similar terms or expressions. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to differ materially from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. Forward-looking statements are based on Telix’s good-faith assumptions as to the financial, market, regulatory and other risks and considerations that exist and affect Telix’s business and operations in the future and there can be no assurance that any of the assumptions will prove to be correct. In the context of Telix’s business, forward-looking statements may include, but are not limited to, statements about: the initiation, timing, progress and results of Telix’s preclinical and clinical trials, and Telix’s research and development programs; Telix’s ability to advance product candidates into, enrol and successfully complete, clinical studies, including multi-national clinical trials; the timing or likelihood of regulatory filings and approvals for Telix’s product candidates, manufacturing activities and product marketing activities; Telix’s sales, marketing and distribution and manufacturing capabilities and strategies; the commercialisation of Telix’s product candidates, if or when they have been approved; Telix’s ability to obtain an adequate supply of raw materials at reasonable costs for its products and product candidates; estimates of Telix’s expenses, future revenues and capital requirements; Telix’s financial performance; developments relating to Telix’s competitors and industry; and the pricing and reimbursement of Telix’s product candidates, if and after they have been approved. Telix’s actual results, performance or achievements may be materially different from those which may be expressed or implied by such statements, and the differences may be adverse. Accordingly, you should not place undue reliance on these forward-looking statements.

©2025 Telix Pharmaceuticals Limited. The Telix Pharmaceuticals® and Illuccix® names and logos are trademarks of Telix Pharmaceuticals Limited and its affiliates – all rights reserved.

BOUNTEOUS x ACCOLITE TO REBRAND AS BOUNTEOUS

Merger creating global leader in digital transformation services hits one year mark

CHICAGO, Jan. 14, 2025 /PRNewswire/ — Bounteous x Accolite today announced that it will unify under the Bounteous brand name globally, following a year of strong market and client reception to the combined company offering and successfully integrating the companies’ go-to market and operating models.

The updated brand name reflects the advantageous combination of Bounteous, a digital innovation partner of the world’s most ambitious brands, and Accolite, a leading digital engineering, cloud, data & AI services provider.

Over the course of the past year, the merger has strengthened the company’s capabilities serving diverse c-suite stakeholders. The company was recognized twelve times in 2024 by analyst groups for the strength of its service offering.

“This merger has enhanced our ability to serve our client stakeholders globally, delivering measurable results through customer experience transformation, data & AI, product engineering, and cloud modernization solutions,” said Keith Schwartz, CEO at Bounteous. “As we look toward 2025 and beyond, we remain committed to using co-innovation to drive value, improve customer experience, and achieve operational efficiencies for our clients.”

Bounteous serves over 300 Fortune 1,000 and high-growth clients, solving their mission-critical problems across industries like Banking, Financial, and Insurance; Consumer Goods and Retail; Healthcare; Logistics; Restaurant and Convenience; Telecommunications; Technology; and Travel & Hospitality.

Bounteous is poised for significant growth in 2025, driven by increasing client demand. With strong talent acquisition efforts underway in India, the company will continue to capitalize on the brand recognition of Accolite in the market by operating under the Bounteous x Accolite name in India through 2025.

About Bounteous
Bounteous is a premier end-to-end digital transformation consultancy dedicated to partnering with ambitious brands to create digital solutions for today’s complex challenges and tomorrow’s opportunities. With uncompromising standards for technical and domain expertise, we deliver innovative and strategic solutions in Strategy, Analytics, Digital Engineering, Cloud, Data & AI, Experience Design, and Marketing. Our Co-Innovation methodology is a unique engagement model designed to align interests and accelerate value creation. Our clients worldwide benefit from the skills and expertise of over 4,000+ expert team members across the Americas, APAC, and EMEA. By partnering with leading technology providers, we craft transformative digital experiences that enhance customer engagement and drive business success. Discover more about our impactful work and expertise by visiting www.bounteous.com and following us on X, LinkedIn, Facebook, and Instagram.

Media Contact
Sara Vinson
sara.vinson@digennaro-usa.com
DiGennaro Communications

Similarvideo Unveils AI Talking Avatar to Transform Video Creation

NEW YORK, Jan. 14, 2025 /PRNewswire/ — Similarvideo, a leader in AI viral video generator, has announced the launch of its revolutionary AI Talking Avatar feature, setting a new standard for creating personalized, engaging, and professional video content.

Developed by Boolv Tech, the AI Talking Avatar feature empowers users to effortlessly design custom AI avatars, streamlining video production while enhancing engagement and impact.

“At Similarvideo, we are committed to redefining video creation through innovation,” said Ken Wang, CEO of Similarvideo. “Our new AI Talking Avatar feature empowers businesses and content creators to produce videos that are not only highly professional but also deeply personal and impactful.”

Transformative Use Cases

  • Product Promotion Videos for Businesses

Similarvideo offers a groundbreaking solution by enabling companies to create high-quality promotional videos with cloned voices and images of influencers. This innovative approach eliminates the need for expensive production crews and extensive on-location shoots, significantly reducing production costs.

By leveraging the credibility and reach of influencer likenesses, companies can maximize their marketing impact and achieve a higher return on investment (ROI)
Learn more: similarvideo.ai/use-cases/marketer

  • Social Media Video Creation for Content Creators

Similarvideo makes content creation seamless for social media platforms like TikTok, Ins and YouTube Shorts. With branded AI avatars and celebrity-inspired voiceovers, creators can produce professional-quality, shareable videos that captivate audiences.

The tool streamlines workflows by automating production tasks, allowing creators to focus on storytelling and audience engagement. By aligning with platform trends, Similarvideo helps influencers consistently deliver standout content and grow their reach effortlessly.
Learn more: similarvideo.ai/use-cases/content-creator

By integrating these advanced capabilities, Similarvideo is driving innovation across industries such as e-commerce, marketing, and content creation. The platform empowers users to:

  • Save time: Automate video production and editing with AI.
  • Reduce costs: Replace expensive filming processes with AI-generated visuals and voiceovers.
  • Create high-ROI ad videos: Achieve superior marketing outcomes by combining personalization and scalability.

Whether it’s helping businesses connect with their target audience or enabling creators to maintain a competitive edge, Similarvideo provides transformative tools that redefine how promotional and social media content is made.

Youtube Video: https://www.youtube.com/watch?v=h_P76pZTRq8

About Similarvideo

Similarvideo is at the forefront of AI-driven video creation, offering intuitive tools that empower businesses and creators to produce captivating content effortlessly. With features like customizable AI Talking Avatars and AI-driven script generators, Similarvideo continues to innovate, making professional-quality video production accessible to all.

To learn more, visit Similarvideo or contact us below.

Media Contact
Ken Wang
CEO, Boolv Tech
support@boolvector.com
SOURCE Boolv Tech

MicroAire appoints Remco Maljers as Head of International Sales

CHARLOTTESVILLE, Va., Jan. 14, 2025 /PRNewswire/ — MicroAire Surgical Instruments, a Marmon Holdings | Berkshire Hathaway company focused on plastic and upper extremity surgery, is pleased to announce the appointment of Remco Maljers as its Head of International Sales.

Remco brings with him extensive experience in global market expansion, a vast network of healthcare professionals worldwide, and a proven track record for driving revenue growth. He draws on over 25 years of experience in medical device business development, including leadership positions at Medtronic, Wright Medical, and NuVasive. During his most recent tenure at Orthofix, Remco spearheaded market expansion efforts across Central and Eastern Europe, the Middle East, Latin America, and Canada.

In his new role, Remco will report directly to MicroAire’s president. He will lead commercial efforts outside the United States, oversee international sales strategy, strengthen relationships with our global partners, and identify new growth opportunities in emerging markets. His leadership will be instrumental in realizing MicroAire’s vision to expand its global footprint and bring innovative solutions to more patients worldwide.

“I am extremely pleased to welcome Remco to MicroAire and am confident in his ability to propel the company to new heights in our international markets,” said Jerome Barrillon, President of MicroAire. “It is our ambition to significantly expand our international presence with our key product lines, and Remco’s appointment is a significant step in moving us forward.”

About MicroAire

Since its first product launch in 1977, MicroAire has been dedicated to designing and manufacturing innovative surgical instruments. This dedication led to the creation of industry-leading devices for body contouring and treating Carpal Tunnel Syndrome and propels MicroAire employees forward every day to empower surgeons and deliver better patient outcomes. MicroAire is a part of Marmon Holdings, Inc., a Berkshire Hathaway company.

Media Contact

David Kraus
Senior Director, Strategy & Customer Excellence
MicroAire Surgical Instruments
david.kraus@microaire.com

Remco Maljers, MicroAire Head of Sales
Remco Maljers, MicroAire Head of Sales

URSROBOT Celebrates a Successful Showcase of NEXMOW M2 at CES 2025

LAS VEGAS, Jan. 14, 2025 /PRNewswire/ — URSROBOT, a leader in AI-driven robotics, is delighted to announce the resounding success of its presentation of the NEXMOW M2 robotic mower at CES 2025. Hosted at the Taiwan Pavilion, Eureka Park, the live demonstrations of the NEXMOW M2 captivated attendees with its cutting-edge technology and transformative approach to commercial landscaping.

URSROBOT Showcases NEXMOW M2, an Advanced AI-Driven Landscaping Solution, to Great Acclaim at CES 2025
URSROBOT Showcases NEXMOW M2, an Advanced AI-Driven Landscaping Solution, to Great Acclaim at CES 2025

CES 2025: A Milestone for NEXMOW M2

The NEXMOW M2, powered by the Qualcomm® QCS6490 processor from Qualcomm Technologies, Inc., providing capabilities such as AI vision for object detection and obstacle avoidance. M2 is designed for more efficiency and more flexibility. It empowers commercial landscaping businesses to optimize labor resources while delivering exceptional lawn maintenance across large-scale terrains.

“We are honored to have showcased the NEXMOW M2 at CES 2025, a global stage for groundbreaking technologies,” said Stephen Chen, CEO of URSROBOT. “The positive reception from attendees and industry leaders validates our mission to revolutionize commercial landscaping with intelligent, scalable, and user-friendly solutions.”

“We are thrilled with the enthusiastic response to the NEXMOW M2 at CES 2025. Powered by the Qualcomm QCS6490 processor, this robotic mower showcases advanced AI vision and obstacle avoidance, enhancing efficiency and flexibility,” stated Erick Hong, Senior Director, Business Development, Qualcomm Technologies, Inc. “We are excited for our continued collaboration with URSROBOT to push forward the robotics and smart home industries.”

Mass Production Scheduled for Spring 2025

Following its strong debut at CES, the NEXMOW M2 is on track for mass production in spring 2025. This next step in its journey reflects URSROBOT’s commitment to delivering innovative, reliable, and efficient robotic solutions to the commercial landscaping industry.

About URSROBOT

URSROBOT is a global leader in AI-powered outdoor robotics, specializing in autonomous solutions for commercial applications. Through its collaboration with Qualcomm Technologies, URSROBOT continues to set  drive innovation in outdoor automation.

CES 2025 marked a pivotal moment in showcasing the future of robotics, and URSROBOT invites stakeholders to join this journey of innovation as the NEXMOW M2 prepares to transform the industry.

Qualcomm is a trademark or registered trademark of Qualcomm Incorporated.

More information available on the URSROBOT website: https://ursrobot.ai/